A New Layer of Control for a Decades-Old Leukemia Drug ndm.ox.ac.uk/news/a-new-laye…
Centre for Medicines Discovery retweeted
New in @NatureComms: a live-cell BRET biosensor to study how PRMT5 inhibitors engage their target in a tumour-context cellular environment (1/4)
Open access paper: doi.org/10.1038/s41467-025-6…
Centre for Medicines Discovery retweeted
New in @ScienceMagazine
An enzyme with a secret life: NUDT5 acts as a molecular “handbrake” on purine synthesis, reshaping how cells build DNA and respond to cancer drugs.
🔗 science.org/doi/10.1126/scie… #ScienceResearch
Centre for Medicines Discovery retweeted
🚀 On July 21, the Chemical Probes Portal celebrates 10 years! Launched after the landmark 2015 @NatChemBio paper by Arrowsmith et al., it now features >1150 compounds, >600 targets, and 1600+ expert reviews—powering better biomedical research. 🧪🔬
👉 chemicalprobes.org
Centre for Medicines Discovery retweeted
Replying to @CmdOxford
@CmdOxford and @Boehringer researchers have discovered the enzymatic mechanism for human ceramide synthase, which could help to develop new treatments for #MetabolicDiseases like #diabetes, #NonAlcoholicFattyLiverDisease and #NASH. 🔬
Read more 👉 ndm.ox.ac.uk/news/researcher…
Revealing Cationic Amino acid Transporter 1 (CAT1) selectivity and binding to Friend Murine Leukemia Virus. Collab of @mingda_ye, @DavidBSauer, @BenediktKessler, @CmdOxford, @OxfordStrubi, @CAMS_COI_Ox, and @im2pact_project
doi.org/10.21203/rs.3.rs-467…
The Bullock group at @CmdOxford and Alison Axtman at @thesgconline report the first chemical probe for the CDKL2 kinase providing an important reagent to interrogate CDKL2-dependent biology. pubs.acs.org/doi/10.1021/acs…
Donna Di Rienzo, a DPhil student at the ARUK ODDI is the recipient of an ARUK Thames Valley Pilot Project Award to discover novel substrates of the E3 ligase IDOL, which is implicated in lipid uptake in the brain.
#ResearchGrant #ARUK #ThamesValley #Collaboration #PilotProject
Ubiquitin C-terminal hydrolase UCH-L1 as an essential regulator of NLRP3-mediated IL-1β production in human macrophages and microglia.
Centre for Medicines Discovery retweeted
Replying to @chembiohub @ACSBioMed
New scaffold to explore ADP-ribose metabolism: By performing SAR studies, we identify a first-in-class, non-covalent dual inhibitor for NUDT5 and NUDT14. (5/5)
📖Read the full story here: pubs.acs.org/doi/10.1021/acs…
#CovalentInhibitors #ChemicalProbes #DarkProteome
The Bullock lab at @CmdOxford together with @OICR_news and @M4KPharma report in J Med Chem the Discovery of Conformationally Constrained ALK2 Inhibitors aimed at future treatments for the childhood brain tumour DIPG. Congratulations Julien Cros, Jong Fu Wong and @melissasweeney_
Join us as Senior Programme Manager and Scientific Coordinator! 🚀Explore our latest opportunities and apply now at cmd.ox.ac.uk/jobs #hiring #Oxford #JobHunt #jobopportunity
Centre for Medicines Discovery retweeted
🎉The Chemical Probes Portal has reached 1,000 compounds!
We review hundreds of high-quality protein inhibitors and other tools for biomedical research, as well as 255 Unsuitables.
Read more:
chemicalprobes.org/news/1000…
#OpenScience #DrugDiscovery #TPD #degraders #ChemicalProbes
Congratulations to team PROTECT, including our own Prof Frank von Delft, on receiving the @CancerGrand Challenges award! They're tackling the tough challenge of #SolidTumours in children @CR_UK, @theNCI
cmd.ox.ac.uk/news/research-t…
New publication on the structure and allosteric regulation of Alzheimer’s target SHIP1 from @Dr_WillB, @Ogileadi, @ARUK_ODDI, @KavliOxford. Including an @XChem_DLS fragment screen with 91 structures.
authors.elsevier.com/sd/arti…
The Bullock lab @CMDOxford and Wilkie Lab @Wilkie_Lab report a new paper identifying mutations in the BTB domain of KCTD15 that perturb BTB oligomerisation and cause a distinctive frontonasal dysplasia syndrome DOI: doi.org/10.1136/jmg-2023-109…
The @katharina_duerr and @DavidBSauer group's new publication reveals export of immunoregulatory sphingosine-1-phosphate is regulated by the signaling lipid PIP2 via its action on the transporter SPNS2. doi.org/10.1016/j.molcel.202…
The Bullock lab @CMDOxford was delighted to collaborate on a new Elife paper reporting selective CDKL5 kinase inhibitors that reveal a role for CDKL5 in hippocampal CA1 physiology. DOI: doi.org/10.7554/elife.88206













